Experience
Regenxbio, Inc. et al.
Sarepta Therapeutics, Inc. et al.
Representing Sarepta in patent litigation involving potential gene therapy for DMD.
Regenxbio, Inc. et al. v. Sarepta Therapeutics, Inc. et al., 1:20-cv-01226, D. Del., Judge Andrews
Genzyme Corporation v. Sarepta Therapeutics, Inc. et al.
Sarepta Therapeutics, Inc. et al.
AbbVie Inc.
Grünenthal GmbH et al. v. Alvogen Pine Brook, Inc. et al.
Grünenthal GmbH et al.
BioDelivery Sciences International, Inc. et al. v. Chemo Research, SL et al.
BioDelivery Sciences International, Inc. et al.
CMC Materials, LLC v. Dupont de Nemours, Inc. et al.
Dupont de Nemours, Inc. et al.
Zimmer Surgical, Inc. et al. v. Stryker Corporation et al.
Zimmer Surgical, Inc.
American Regent, Inc. v. Pharmacosmos Therapeutics Inc. et al.
American Regent, Inc.
Rocket Pharmaceuticals, Inc. v. Lexeo Therapeutics, Inc., et al.
Rocket Pharmaceuticals, Inc.
Genzyme Corporation et al. v. Novartis Gene Therapies, Inc. et al.
Novartis Gene Therapies, Inc. et al.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.